Bovhyaluronidase azoximer significantly reduces exercise intolerance in patients with long-term pulmonary sequelae of COVID-19
Longidaza significantly reduced exertional desaturation and dyspnea, as well as improved distance walked during the six-minute walk test. The drug's effects on exercise tolerance were sustained for over 100 days after treatment.